- Home
- BSX
as 12-20-2024 3:32pm EST
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | MARLBOROUGH |
| Market Cap: | 129.7B | IPO Year: | 1992 |
| Target Price: | $96.41 | AVG Volume (30 days): | 5.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.21 | EPS Growth: | 47.19 |
| 52 Week Low/High: | $55.60 - $91.93 | Next Earning Date: | 01-29-2025 |
| Revenue: | $15,911,000,000 | Revenue Growth: | 15.66% |
| Revenue Growth (this year): | 17.67% | Revenue Growth (next year): | 12.68% |
Stock Insider Trading Activity of Boston Scientific Corporation (BSX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Carruthers Wendy | BSX | EVP, Human Resources | Dec 2 '24 | Sell | $90.78 | 6,983 | $633,916.74 | 29,308 | |
| Woodworth Emily | BSX | SVP, Global Controller and CAO | Nov 27 '24 | Sell | $90.65 | 1,336 | $121,105.19 | 2,957 | |
| Butcher Arthur C | BSX | EVP& Grp Pres, MedSurg & APAC | Nov 25 '24 | Sell | $89.27 | 14,010 | $1,250,664.29 | 978 | |
| LUDWIG EDWARD J | BSX | Director | Nov 21 '24 | Sell | $91.63 | 4,877 | $446,901.94 | 39,398 | |
| Sorenson John Bradley | BSX | EVP, Global Operations | Nov 8 '24 | Sell | $87.66 | 30,580 | $2,680,572.47 | 39,706 | |
| Mahoney Michael F | BSX | Chairman, President & CEO | Nov 5 '24 | Sell | $84.96 | 162,778 | $13,794,850.92 | 1,521,205 | |
| Carruthers Wendy | BSX | EVP, Human Resources | Nov 1 '24 | Sell | $84.33 | 6,983 | $588,876.39 | 29,308 | |
| Mahoney Michael F | BSX | Chairman, President & CEO | Oct 7 '24 | Sell | $84.63 | 162,777 | $13,775,791.62 | 1,521,205 | |
| Fitzgerald Joseph Michael | BSX | EVP & Group Pres, Cardiology | Oct 7 '24 | Sell | $85.00 | 132,527 | $11,264,887.77 | 160,467 | |
| Carruthers Wendy | BSX | EVP, Human Resources | Oct 1 '24 | Sell | $83.86 | 6,983 | $585,594.38 | 29,308 |
Latest Boston Scientific Corporation News
BSX Breaking Stock News: Dive into BSX Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Medtronic Stock Declines 5.6% in a Month: Time to Buy the Dip?
Simply Wall St.
2 days ago
Should You Be Adding Boston Scientific (NYSE:BSX) To Your Watchlist Today?
Zacks
2 days ago
All You Need to Know About Boston Scientific (BSX) Rating Upgrade to Buy
Zacks
3 days ago
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?
TipRanks
3 days ago
Boston Scientific price target raised to $110 from $100 at Truist
Zacks
3 days ago
Should You Retain Henry Schein Stock in Your Portfolio Right Now?
MedTech Dive
3 days ago
Boston Scientific updates cryoablation catheter instructions after 4 death reports
MT Newswires
3 days ago
Baird Raises Boston Scientific Price Target to $102 From $100, Maintains Outperform Rating
Compare BSX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BSX Boston Scientific Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.